This post was originally published on this site
Core earnings came in at $1.72 cents per share for the three months ended June 30, on revenue of about $10.8 billion.
Analysts on average were expecting profit of $1.56 cents per share on revenue of around $10.5 billion, Refinitiv data showed.
The London-listed company also raised its full-year revenue guidance, saying it expects it to rise by a percentage in the low twenties rather than the high teens forecast previously.
On Friday, the company also revealed the replacement for non-executive Chairman Leif Johansson – Michel Demaré will take over once Johansson retires next year. Demaré currently serves as the chair of AstraZeneca (NASDAQ:AZN)’s remuneration committee.
Johansson became chairman in 2012, around the same time Frenchman Pascal Soriot took charge as chief executive.
